Howard Ozer

9.7k citations

143 papers · 5.5k indexed · 2 hit papers · h-index 38

Impact in

Hematology top 0.5%
- Hematopoietic Stem Cell Transplantation
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments

Papers in

Genetics 44
- Chronic Lymphocytic Leukemia Research 39
- Blood disorders and treatments 11
Hematology 35
- Chronic Myeloid Leukemia Treatments 12

Co-authors: Jeffrey Crawford John A. Glaspy Ronald G. Stoller Mark G. Kris Gary H. Lyman Morgan E. Stewart Vincent J. Picozzi Imad A. Tabbara
Journals: Journal of Clinical Oncology (14 papers)Blood (12 papers)The Journal of Immunology (6 papers)JNCI Journal of the National Cancer Institute (5 papers)Seminars in Oncology (4 papers)
Partner nations: United States Türkiye Japan

In The Last Decade

Howard Ozer

141 papers receiving 5.2k citations

Hit Papers

align trajectories log scale

2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines 2000 · 629 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2000 Journal of Clinical Oncology
1991 New England Journal of Medicine

Peers

Countries citing papers authored by Howard Ozer

Since Specialization

Citations

This map shows the geographic impact of Howard Ozer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Ozer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Ozer more than expected).

Fields of papers citing papers by Howard Ozer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard Ozer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Ozer. The network helps show where Howard Ozer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Howard Ozer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Howard Ozer Line = papers co-authored together Howard Ozer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q) Cancer Research ·Liping Li, Yue Sheng, Wenshu Li, Chao Hu, Nupur Mittal, Kaoru Tohyama, Sidra Gul, You‐Yang Zhao, Howard Ozer, Tongyu Zhu, Zhijian Qian	2017	17
2	Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology Molecular Therapy — Nucleic Acids ·Sven Kruspe, David D. Dickey, Muhammad Khalid Ramli, Jennifer Nicole. Markham, Matthew J. Miller, 竹石文彦, C. Dauccia, Wade R. Gutierrez, Jyothi Prakash, Nailin Muna, Timothy Ginader, Bruce A. Smith, William A. O'Keefe, Gilberto Figueroa-Alfaro, Howard Ozer, Alexandra Thomas, James O McNamara, Carlos H.F. Chan, Paloma H. Giangrande	2017	31
3	Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008 Supportive Care in Cancer ·Elizabeth Tarlov, Kevin T. Stroupe, Todd A. Lee, Matúš Pošvanc, L. E. Prior, Laura C. Michaelis, Howard Ozer, Qichen Duan, Denise M. Hynes	2011	15
4	Low Incidence of Neutropenic Events in Patients with Lymphoma Receiving First-Cycle Pegfilgrastim with Chemotherapy: Results from a Prospective Community-Based Study Clinical Lymphoma & Myeloma ·Stephen J. Noga, J. K. Choksi, Beiying Ding, Lyndah Dreiling, Howard Ozer	2007	8
5	Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation ·Rammurti T. Kamble, George B. Selby, Martha P. Mims, Mohamed A. Kharfan‐Dabaja, Howard Ozer, James N. George	2006	60
6	Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia PubMed ·Jeffrey Crawford, John A. Glaspy, Ronald G. Stoller, Dianne Tomita, Francilainy Karina de Andrade Silva, Brian McGuire, Howard Ozer	2005	37
7	Microbial contamination of hematopoietic progenitor cell grafts—incidence, clinical outcome, and cost‐effectiveness: an analysis of 735 grafts Transfusion ·Rammurti T. Kamble, Shubham Pant, George B. Selby, Mohamed A. Kharfan‐Dabaja, Sanjay Sethi, Helmut Kettenmann, Jannatul Ferdause Rifat, Howard Ozer	2005	51
8	Perspectives in the treatment of colorectal cancer Seminars in Oncology ·Howard Ozer, Robert B. Diasio	2004	6
9	Clinical issues and treatment advances in thrombocytopenia: Introduction Seminars in Hematology ·Howard Ozer	2000	3
10	Carcinoma of the Kidney, Testis, and Rare Urologic Malignancies American Journal of Clinical Oncology ·Todd J. Kumler '07, Luc Baert, Luther W. Brady, Dirk De Ridder, Hans Goethuys, Rien J.M. Nijman, Raymond Oyen, Howard Ozer, Tania Roskams, John P. Stein, L Stockx, A. van Oosterom, H. P. Van Poppel, Rebecca Minerva Guerrero	2000	3
11	Phase I Trial of Etoposide, Carboplatin, and GM-CSF in Extensive Small-Cell Lung Cancer American Journal of Clinical Oncology ·Sharon D. Luikart, James E. Herndon, Donna Hollis, Margaret MacDonald, L. Herbert Maurer, Jeffrey Crawford, Gerald H. Clamon, Jonathan Wright, Michael C. Perry, Howard Ozer, Mark R. Green	1997	3
12	American Society of Clinical Oncology guidelines for the clinical use of hematopoietic colony-stimulating factors Current Opinion in Hematology ·Howard Ozer	1996	19
13	Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. PubMed ·Michael R. Kanost, Frederick R. Davey, B. Peterson, Charles A. Schiffer, R T Silver, Howard Ozer, H M Golomb, C. D. Bloomfield	1995	28
14	Using a Community Clinical Trials Network for Treatment, Prevention, and Control Research: Assuring Access to State-of-the-Art Cancer Care Cancer Investigation ·Arnold D. Kaluzny, Richard B. Warnecke, Linda Lacey, Timothy P. Johnson, Dennis B. Gillings, Howard Ozer	1995	7
15	Combination trial of subcutaneous recombinant α₂b interferon and oral cyclophosphamide in follicular low‐grade non‐Hodgkin's lymphoma Medical and Pediatric Oncology ·Howard Ozer, James R. Anderson, B. A. Peterson, Daniel R. Budman, M. Robert Cooper, B. J. Kennedy, Richard T. Silver, Edward S. Henderson, David B. Duggan, Carl Cabanilla, Clara D. Bloomfield, Arlan J. Gottlieb	1994	11
16	Transcription Termination/Polyadenylation Occurs at Multiple Sites in the Human Type I Interferon Receptor Gene Journal of Interferon Research ·M. Jodi, Patrick J. Vojta, Victor K. M. Han, David C. Lee, Howard Ozer	1993	1
17	Interferon‐α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia British Journal of Haematology ·Maria R. Baer, Howard Ozer, Kenneth A. Foon	1992	73
18	Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients Leukemia & lymphoma ·Harvey M. Golomb, Mark J. Ratain, A Fefer, James E. Thompson, C. Portlock, Howard Ozer, Rosemarie Mick, P Cannon-Brookes, Robert J. Israel, Eric M. Bonnem	1991	2
19	Evaluating Organizational Design To Assure Technology Transfer: The Case of the Community Clinical Oncology Program JNCI Journal of the National Cancer Institute ·A D Kaluzny, Taylor H. Ricketts, Richard B. Warnecke, João Batista de Paiva, James H. Morrissey, D Gillings, Edward J. Sondik, Howard Ozer, John A. Goldman	1989	35
20	In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. The Journal of Experimental Medicine ·Howard Ozer, J. Wayne Cowens, Michael Colvin, Е.Н. Башилова, David B. Sheedy	1982	91

About Howard Ozer

Howard Ozer is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Oncology and Immunology, having authored 143 papers that have together received 5.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (39 papers), Lymphoma Diagnosis and Treatment (32 papers), Neutropenia and Cancer Infections (21 papers), Immune Cell Function and Interaction (12 papers), Chronic Myeloid Leukemia Treatments (12 papers), Blood disorders and treatments (11 papers), Immunodeficiency and Autoimmune Disorders (11 papers) and T-cell and B-cell Immunology (10 papers). The work is most often cited by research in Hematology (1.2k citations), Genetics (1.1k citations), Oncology (2.6k citations), Immunology (1.1k citations) and Pathology and Forensic Medicine (860 citations). Howard Ozer has collaborated with scholars based in United States, Türkiye and Japan. Frequent co-authors include Jeffrey Crawford, John A. Glaspy, Ronald G. Stoller, Mark G. Kris, Gary H. Lyman, Morgan E. Stewart, Vincent J. Picozzi, Imad A. Tabbara, Roy E. Smith and John Grous. Their work appears in journals such as Journal of Clinical Oncology, Blood, The Journal of Immunology, JNCI Journal of the National Cancer Institute and Seminars in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact